BBHC
SUPN icon

Brown Brothers Harriman & Co’s Supernus Pharmaceuticals SUPN Stock Holding History

Brown Brothers Harriman & Co’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.7K Hold
187
– – ﹤0.01% 1454
2026
Q1 		$9.67K Buy
187
+16
+9% +$815 ﹤0.01% 1364
2025
Q4 		$8.5K Sell
171
-323
-65% -$15.7K ﹤0.01% 1375
2025
Q3 		$23.6K Buy
+494
New +$19.9K ﹤0.01% 1135
2018
Q1 		– Sell
-383
Closed -$15K – 1091
2017
Q4 		$15K Buy
+383
New +$15.1K ﹤0.01% 693
2016
Q1 		– Sell
-200
Closed -$3K – 734
2015
Q4 		$3K Hold
200
– – ﹤0.01% 701
2015
Q3 		$3K Sell
200
-200
-50% -$3.72K ﹤0.01% 765
2015
Q2 		$7K Buy
+400
New +$5.69K ﹤0.01% 665

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Brown Brothers Harriman & Co's SUPN Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 187 shares worth $8.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1454.

Brown Brothers Harriman & Co first reported a position in SUPN in Q2 2015 and has held it in 8 quarters since. The position peaked at $23.6K in Q3 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Brown Brothers Harriman & Co held 187 shares of Supernus Pharmaceuticals worth $8.7K as of Q2 2026.
  • Brown Brothers Harriman & Co left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1454 holding.
  • Brown Brothers Harriman & Co first reported a position in Supernus Pharmaceuticals in Q2 2015 and has held it in 8 quarters since.
  • Brown Brothers Harriman & Co's Supernus Pharmaceuticals position peaked at $23.6K in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.